Patent intelligence · US
US 12370181
Regimens of estrogen receptor antagonists
Regimens of estrogen receptor antagonists
Patent details — US 12370181
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 29, 2025
- Expiration
- Jul 24, 2045
- Applicant
- Olema Pharmaceuticals, Inc.
- Claims
- 10
- CPC classes
- A61K, A61K31/137, A61K31/138, A61K31/436
Quick answer
US 12370181 (Regimens of estrogen receptor antagonists) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Olema Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/137, A61K31/138, A61K31/436, A61K31/437, A61K31/4439
More from Olema Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428379
Acylsulfonamide KAT6A inhibitors
granted -
US 11672785
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 11229630
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10624878
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10292971
Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
granted -
US 9018244
Benzopyran compounds, compositions and uses thereof
granted -
US 8071545
Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
granted
Frequently asked questions
What is US patent 12370181?
US 12370181 (Regimens of estrogen receptor antagonists) is held by Olema Pharmaceuticals, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12370181?
Olema Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 12370181 expire?
Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.